Search results for "dosage"

showing 10 items of 516 documents

Calorimetric and viscosimetric investigation of the interaction between α,β-polyasparthydrazide and sodium dodecyl sulfate micelles

1993

Abstract The interaction between α,β-polyasparthydrazide (PAHy) and sodium dodecyl sulfate (SDS) micelles in aqueous solution was investigated by calorimetry and viscosimetry. The dependence of the enthalpic effect due to this interaction upon the surfactant concentration was rationalized in terms of a progressive binding of SDS micelles to the polymeric backbone. The analysis of the calorimetric data allow evaluation of the binding ability of SDS micelles to the polymeric chain. The viscosimetric behavior of SDS plus PAHy aqueous solutions, discussed in terms of the parameter F [F = ηrel(PAHy) + ηrel(PAHy) − ηrel(SDS+PAHy)], confirms the occurence of the interaction between SDS micelles an…

Binding abilitychemistry.chemical_compoundChromatographyAqueous solutionPulmonary surfactantchemistryPolymer chemistryPharmaceutical ScienceCalorimetrySodium dodecyl sulfateMicelleDosage formMacromoleculeInternational Journal of Pharmaceutics
researchProduct

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

2007

AbstractIntegrative genomic and gene-expression analyses have identified amplified oncogenes in B-cell non-Hodgkin lymphoma (B-NHL), but the capability of such technologies to localize tumor suppressor genes within homozygous deletions remains unexplored. Array-based comparative genomic hybridization (CGH) and gene-expression microarray analysis of 48 cell lines derived from patients with different B-NHLs delineated 20 homozygous deletions at 7 chromosome areas, all of which contained tumor suppressor gene targets. Further investigation revealed that only a fraction of primary biopsies presented inactivation of these genes by point mutation or intragenic deletion, but instead some of them w…

BiopsyDNA Mutational AnalysisGene DosageVesicular Transport ProteinsApoptosisBiochemistryEpigenesis Geneticimmune system diseaseshemic and lymphatic diseasesChromosomes HumanGenes Tumor SuppressorPromoter Regions GeneticSorting NexinsOligonucleotide Array Sequence AnalysisSequence DeletionBcl-2-Like Protein 11HomozygoteChromosome MappingNuclear ProteinsNucleic Acid HybridizationRNA-Binding ProteinsHematologyDNA NeoplasmBCL10Gene Expression Regulation Neoplasticmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2DNA methylationLymphoma B-CellTumor suppressor geneImmunologyBiologyGene dosageCell Line TumorProto-Oncogene ProteinsmedicineCyclin-Dependent Kinase Inhibitor p18HumansPoint MutationGene SilencingB cellAdaptor Proteins Signal TransducingHomeodomain ProteinsMembrane ProteinsCell BiologyDNA Methylationmedicine.diseaseMolecular biologyLymphomaCancer researchMantle cell lymphomaApoptosis Regulatory ProteinsCarrier ProteinsDiffuse large B-cell lymphomaTranscription Factors
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Bisoprolol Fumarate

2014

Abstract Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing bisoprolol as the sole active pharmaceutical ingredient (API) are reviewed. Bisoprolol is classified as a Class I API according to the current Biopharmaceutics Classification System (BCS). In addition to the BCS class, its therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions, and reported BE/bioavailability problems are taken into consideration. Qualitative compositions of IR tablet dosage forms of bisoprolol with a marketing authorization (MA) in ICH (Inter…

Bisoprolol FumarateCell Membrane PermeabilityAdrenergic beta-AntagonistsBiological AvailabilityPharmaceutical ScienceExcipientPharmacologyBioequivalenceDosage formBiopharmaceuticsExcipientsmedicineBisoprololHumansTissue DistributionBiotransformationChromatography High Pressure LiquidHeart FailureActive ingredientChemistryStereoisomerismHydrogen-Ion ConcentrationBiopharmaceutics Classification SystemBioavailabilityIntestinal AbsorptionSolubilityTherapeutic EquivalencyBisoprololmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Hypothalamic reactive oxygen species are required for insulin-induced food intake inhibition: an NADPH oxidase-dependent mechanism

2009

1939-327X (Electronic) Journal Article Research Support, Non-U.S. Gov't; OBJECTIVE: Insulin plays an important role in the hypothalamic control of energy balance, especially by reducing food intake. Emerging data point to a pivotal role of reactive oxygen species (ROS) in energy homeostasis regulation, but their involvement in the anorexigenic effect of insulin is unknown. Furthermore, ROS signal derived from NADPH oxidase activation is required for physiological insulin effects in peripheral cells. In this study, we investigated the involvement of hypothalamic ROS and NADPH oxidase in the feeding behavior regulation by insulin. RESEARCH DESIGN AND METHODS: We first measured hypothalamic RO…

Blood GlucoseMaleReactive Oxygen Species/*metabolismHypothalamusHomeostasis/drug effects/physiologyInbred C57BLCerebral VentriclesCerebral Ventricles/drug effects/*physiologyMiceHomeostasisInsulinAnimalsBlood Glucose/metabolismHypothalamus/*physiologyInsulin/administration & dosage/blood/*pharmacologyNADPH OxidasesEnergy Intake/drug effects/*physiologyNADPH Oxidase/*metabolismGlutathioneGlutathione/metabolismMice Inbred C57BLOriginal ArticleEnergy IntakeReactive Oxygen SpeciesEnergy MetabolismSignal Transduction
researchProduct

Cyclosporine A + Glybenclamide. Effect on Glucose Metabolism: Preliminary Results

1989

Cyclosporine A (CsA) is an immunosuppressive drug which determines, at high dosage, glucose intolerance (1). Different drugs present a pharmacological interaction with CsA increasing or reducing its blood level (2). To investigate the role of Glybenclamide (HB419), a sulphonilureic oral antidiabetic drug of large use, on CsA glucose metabolic effect, we have administered CsA + HB419 in rats. The aim of our work is to evaluate if HB419 influences CsA blood levels and if it improves glucose tolerance.

Blood levelDrugbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectCarbohydrate metabolismPharmacologymedicine.diseaseHydropic degenerationImmunosuppressive drugHigh dosageMetabolic effectsmedicinebusinessmedia_common
researchProduct

Influence of Age on Cerebral Housekeeping Gene Expression for Normalization of Quantitative Polymerase Chain Reaction after Acute Brain Injury in Mice

2015

To prevent methodological errors of quantitative PCR (qPCR) normalization with reference genes is obligatory. Although known to influence gene expression, impact of age on housekeeping gene expression has not been determined after acute brain lesions such as traumatic brain injury (TBI). Therefore, expression of eight common control genes was investigated at 15 min, 24 h, and 72 h after experimental TBI in 2- and 21-month-old C57Bl6 mice. Expression of β2-microglobulin (B2M), β-actin (ActB), and porphobilinogen deaminase (PBGD) increased after TBI in both ages. β2M demonstrated age-dependent differences and highest inter- and intragroup variations. Expression of cyclophilin A, glyceraldehyd…

Brain ChemistryMaleAgingDNA ComplementaryGenes EssentialInterleukin-6Porphobilinogen deaminaseGene DosageBiologyPolymerase Chain ReactionMolecular biologyHousekeeping geneMice Inbred C57BLMiceCyclophilin AReal-time polymerase chain reactionGene Expression RegulationHypoxanthine-guanine phosphoribosyltransferaseBrain InjuriesReference genesGene expressionAnimalsRNANeurology (clinical)GeneJournal of Neurotrauma
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride.

2020

Abstract In this monograph, literature data is reviewed to evaluate the feasibility of waiving in vivo bioequivalence testing and instead applying the Biopharmaceutics Classification System (BCS) based methods to the approval of immediate-release solid oral dosage forms containing moxifloxacin hydrochloride as the sole active pharmaceutical ingredient. To facilitate the feasibility decision, solubility and permeability and dissolution characteristics in the context of the BCS, therapeutic index, therapeutic use, pharmacokinetic parameters, bioequivalence/bioavailability issues, drug-excipient interactions and other relevant data were taken into consideration. Moxifloxacin is a BCS class I d…

Break pointBiowaiverMoxifloxacinPharmaceutical ScienceAdministration OralBiological AvailabilityContext (language use)02 engineering and technologyPharmacologyBioequivalenceMoxifloxacin hydrochloride030226 pharmacology & pharmacyDosage formMoxifloxacin hydrochloridePermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicineMoxifloxacinMedicinePharmacokineticsTherapeutic indexActive ingredientDosage Formsbusiness.industryBiopharmaceutics Classification System021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemBioavailabilityPharmacodynamicsSolubilityTherapeutic Equivalency0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.

2013

Abstract Activation of the transcription factor PPARγ by the n-3 fatty acid docosahexaenoic acid (DHA) is implicated in controlling proinflammatory cytokine secretion, but the intracellular signaling pathways engaged by PPARγ are incompletely characterized. Here, we identify the adapter-encoding gene SOCS3 as a critical transcriptional target of PPARγ. SOCS3 promoter binding and gene transactivation by PPARγ was associated with a repression in differentiation of proinflammatory T-helper (TH)17 cells. Accordingly, TH17 cells induced in vitro displayed increased SOCS3 expression and diminished capacity to produce interleukin (IL)-17 following activation of PPARγ by DHA. Furthermore, naïve CD4…

CD4-Positive T-LymphocytesCancer ResearchAngiogenesisMammary Neoplasms Experimental/genetics/pathology/prevention & controlSuppressor of Cytokine Signaling Proteinsddc:616.07BioinformaticsTransactivationMice0302 clinical medicineTumor Burden/drug effects/geneticsSOCS3Docosahexaenoic Acids/administration & dosage/pharmacologyPromoter Regions GeneticMice Knockout0303 health sciencesMice Inbred BALB CChemistryReverse Transcriptase Polymerase Chain ReactionInterleukin-17InterleukinCell DifferentiationCell biologyTumor BurdenOncology030220 oncology & carcinogenesisFemaleRNA InterferenceInterleukin 17Th17 Cells/drug effects/metabolismTranscriptional ActivationDocosahexaenoic AcidsBlotting WesternMice NudeCD4-Positive T-Lymphocytes/drug effects/metabolismProinflammatory cytokine03 medical and health sciencesSuppressor of Cytokine Signaling Proteins/genetics/metabolismCell Line TumorAnimalsTranscription factor030304 developmental biologyMammary Neoplasms ExperimentalPromoter Regions Genetic/geneticsDietMice Inbred C57BLPPAR gammaInterleukin-17/metabolismCell cultureSuppressor of Cytokine Signaling 3 ProteinCell Differentiation/drug effectsPPAR gamma/agonists/genetics/metabolismTh17 CellsCancer research
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer

2010

El pdf del artículo es la versión de autor.-- et al.

Cancer ResearchMicroarrayGene DosageGene ExpressionEstrogen receptorBreast NeoplasmsGene dosageMiceBreast cancerOriginal ReportsAnimalsHumansMedicineGenetic Predisposition to DiseaseCopy-number variationskin and connective tissue diseasesSequence Deletionbusiness.industryCancerPeriod Circadian ProteinsPrognosismedicine.diseaseSurvival AnalysisDisease Models AnimalReceptors EstrogenOncologyChromosomes Human Pair 1Cancer researchFemaleBreast diseaseNeoplasm Recurrence LocalbusinessTamoxifenmedicine.drugJournal of Clinical Oncology
researchProduct